GGHC
IMPL

Gilder Gagnon Howe & Co’s Impel Pharmaceuticals Inc. Common Stock IMPL Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio IMPL Stock Details IMPL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-142,631
Closed -$535K – 263
2022
Q4 		$535K Sell
142,631
-65
-0% -$237 0.01% 215
2022
Q3 		$695K Buy
142,696
+5,302
+4% +$40.6K 0.01% 210
2022
Q2 		$1.28M Buy
+137,394
New +$1M 0.02% 188

Other funds holding IMPL

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LM
Lasry Marc $15.1M AUM 10.39% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $375M AUM 72.65% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Gilder Gagnon Howe & Co's IMPL Position: Q1 2023 in Review

Gilder Gagnon Howe & Co sold out of Impel Pharmaceuticals Inc. Common Stock (IMPL) in Q1 2023, closing a stake of 142,631 shares — an estimated $535K sold.

Gilder Gagnon Howe & Co first reported a position in IMPL in Q2 2022 and held it in 3 quarters. The position peaked at $1.28M in Q2 2022. 32 funds tracked by Wall St. Rank hold IMPL as of Q1 2023.

  • Gilder Gagnon Howe & Co reported no remaining Impel Pharmaceuticals Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 142,631 Impel Pharmaceuticals Inc. Common Stock shares in Q1 2023, an estimated $535K.
  • Gilder Gagnon Howe & Co first reported a position in Impel Pharmaceuticals Inc. Common Stock in Q2 2022 and held it in 3 quarters.
  • Gilder Gagnon Howe & Co's Impel Pharmaceuticals Inc. Common Stock position peaked at $1.28M in Q2 2022.
  • 32 funds tracked by Wall St. Rank held Impel Pharmaceuticals Inc. Common Stock as of Q1 2023.

Based on Gilder Gagnon Howe & Co's 13F filing for Q1 2023, filed 15 May 2023.